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of  experts  by  searching  and  analysing  the  literature,  and  then  underwent  a consensus  process  using  a
modiﬁed  Delphi  procedure.  The  statements  report  recommendations  regarding  the  most  appropriate
use  and  timing  of  various  imaging  techniques  and  of  endoscopic  ultrasound,  the role  of circulating  and
intracystic  markers  and  the  pathologic  evaluation  for  the diagnosis  and  follow-up  of cystic  pancreatic
neoplasms.
ca  Itaancreatic neoplasms ©  2014  Editrice  Gastroenterologi
. Introduction
Cystic pancreatic neoplasms (CPNs) have been increasingly
dentiﬁed over the past two decades due to the widespread use of
igh-resolution non-invasive abdominal imaging.
The characterisation and management of these cysts are a
ilemma since there is a signiﬁcant overlap in the morphology
f benign and premalignant lesions; the 2010 WHO  classiﬁcation
f CPNs is reported in Table 1 [1]. Of these entities, ﬁve types of
eoplasms account for approximately 90% of all cystic tumours
f the pancreas: intraductal papillary mucinous neoplasms
IPMNs) (either main duct, branch duct or mixed), mucinous
ystic neoplasms (MCNs), serous cystic neoplasms (SCNs) and
seudopapillary neoplasms.
CPNs  are mostly detected incidentally when non-invasive
bdominal imaging is performed for unrelated indications. The
revalence of incidental pancreatic cystic lesions in the adult
opulation is high, and ranges from 2.6 to 19.6% [2–4]. Autopsy
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series report an increase in CPN prevalence with age: 8% below
70 yrs of age and 18%, 30% and 35% in the age ranges of 70–79,
80–89 and >90 yrs of age, respectively [5]. The size and number
of CPNs (per patient) also increase with age [2–4]. Of note, a
non-negligible proportion of CPNs, especially those with small
diameters, are usually not described in imaging reports in patients
without a past history of pancreatic disease (69% of cystic lesions
with a mean diameter of 6 mm were not reported) [3].
While there is now an increased awareness of these lesions, their
natural history is still partially unclear, and optimal management
is still under debate.
Therefore,  clinicians are faced with a high, and ever increasing,
prevalence of CPNs due to population ageing, and management dif-
ﬁculties of these lesions, with the inherent risks of over- or misuse
of diagnostic tests, entailing unnecessary risk and discomfort for
patients and resources wasted for the health care system.
Evidence-based practice guidelines exist for pancreatic muci-
nous neoplasms [6]; European consensus statements regarding all
CPNs have also been drafted [7].
Comprehensive guidelines regarding all CPNs, oriented by clin-
ical patient presentation rather than the pathologic diagnosis, and
based on a sound consensus methodology, are however lacking.
Additionally, in Europe, the national welfare systems are sig-
niﬁcantly different, and the availability of high-end diagnostic
techniques is not uniform in different countries. Thus, guidelines
need to be tailored to the speciﬁc country [8].
Of note, consensus regarding clinical practice is particularly
Open access under CC BY-NC-ND license.valuable in this context where limited data are available and health
providers are faced with difﬁcult clinical decisions; controversial
issues still exist in the evaluation and management of CPNs, particu-
larly regarding lesion size, the presence of high-risk lesion features,
pen access under CC BY-NC-ND license.
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Table 1
WHO  classiﬁcation of cystic pancreatic tumours, 2010.
Epithelial tumours
Benign
Acinar  cell cystadenoma
Serous  cystadenoma
Premalignant lesions
Intraductal  papillary mucinous neoplasm (IPMN)
Mucinous cystic neoplasm (MCN)
Malignant lesions
Acinar  cell cystadenocarcinoma
Intraductal papillary mucinous carcinoma (IPMN) with an associated invasive
carcinoma
Mucinous cystic neoplasm (MCN) with an associated invasive carcinoma
Serous cystadenocarcinoma
Solid-pseudopapillary neoplasm
Neuroendocrine neoplasms with cystic degeneration
Mesenchymal tumours
Lymphangioma, NOS
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he role of different diagnostic techniques, and the accuracy of
arkers and cytology for CPN deﬁnition.
Therefore, the Italian Association of Hospital Gastroenterolo-
ists and Endoscopists (Associazione Italiana Gastroenterologi ed
ndoscopisti Ospedalieri, AIGO) and the Italian Association for
he Study of the Pancreas (Associazione Italiana per lo Studio del
ancreas, AISP) have produced the present consensus guidelines
hich: (1) are limited to the diagnostic work-up and follow-up
f all CPNs according to WHO  classiﬁcation (and excluding cys-
ic inﬂammatory lesions of the pancreas due to acute or chronic
ancreatitis with a compatible patient history), (2) are based on a
ound consensus methodology (see Appendix D) to allow evalua-
ion of published data and their quality, and to synthesise them
ith expert opinions wherever data in the literature are either
issing or of low quality, (3) are clinically oriented in order to
ddress the clinical scenarios encountered when caring for patients
ith CPNs, and (4) consider also the characteristics of the Italian
ealth Care System, with its inherent availability of different diag-
ostic techniques. The consensus was reached for each statement
ccording to the Delphi procedure [9] and both the level of evi-
ence (EL) and the grade of recommendation (RG) were reported
ccording to the Oxford criteria [10]. The following recommenda-
ions are applicable only to those patients for whom a therapeutic
pportunity is suitable at the time of diagnosis or during the
ollow-up. No additional examinations are required when the
atient, after diagnosis, is found to be unﬁt for any treatment and
symptomatic.
. Consensus statements
.1.  Indications for work-up
1)  Which patients with pancreatic cystic lesions need an addi-
ional diagnostic work-up, after exclusion of those unsuitable for
reatment or unwilling to undergo diagnostic work-up?
Statement
All  patients with pancreatic cystic neoplasms require a diag-
ostic work-up [11–18].
Evidence  level 2a, Recommendation grade B, Agreement 96%
Comment
All  patients with pancreatic cystic neoplasms, symptomatic or
symptomatic, require a diagnostic work-up in order to evaluate
ppropriate treatment or surveillance.r Disease 46 (2014) 479–493
Patients with asymptomatic, small (<1 cm)  pancreatic cystic
neoplasms also require a diagnostic work-up since malignancy can
occur (2%). If the cystic lesion was  discovered by a high resolution
technique (such as MRI  or MDCT), no further investigation is
usually needed.
2)  Deﬁne clinical presentation on the basis of the pres-
ence/absence of sign/symptoms.
In  symptomatic patients, what are the signs/symptoms of a pan-
creatic cystic lesion?
Statement
Signs/symptoms of a pancreatic cystic lesion include: abdom-
inal pain, acute pancreatitis, nausea, vomiting, weight loss
also due to exocrine pancreatic insufﬁciency with steatorrhea,
anorexia, recent onset or worsening diabetes, obstructive jaun-
dice and a palpable mass [14,19–33].
Evidence level 4, Recommendation grade D, Agreement 94%
Comment
Symptoms can differ according to the type of cystic lesion:
IPMNs are often discovered after pancreatitis; large MCNs and
SCNs may  be discovered as a result of the presence of a palpable
abdominal mass. Jaundice, severe abdominal pain, weight loss,
anorexia and diabetes are more likely associated with malignant
behaviour.
3) In the setting of symptomatic patients, which diagnostic tech-
nique/s is/are necessary before treatment?
Statement
In the setting of symptomatic patients, high resolution
imaging techniques, including MRI  with MRCP and/or MDCT
with a pancreatic protocol, represent the ﬁrst diagnostic step
[12,34–47].
Evidence level 1a, Recommendation grade A, Agreement 98%
Comment
MRI  with MRCP and/or MDCT characterise the cyst and stage the
neoplasm (i.e. local inﬁltration, distant metastases). Since surgery
is required for all symptomatic resectable cystic lesions no addi-
tional procedures are usually necessary. If distant metastases are
suspected, but not clearly demonstrated, PET/CT with 18FDG can be
performed.
If local inﬁltration is suspected, MDCT is usually enough to
assess the inﬁltration; in doubtful cases, EUS with or without FNA
can also be carried out.
4)  Which data regarding personal or familial history, and
which laboratory ﬁndings should be considered in asymptomatic
patients?
Statement
A family history for pancreatic cancer and/or other malig-
nancies, and a personal and familial history consistent with Von
Hippel–Lindau (VHL) disease should be considered.
Serum carbohydrate antigen (CA) 19-9 and glucose levels
should be evaluated as well [48–59].
Evidence level 2a, Recommendation grade B, Agreement 94%
Comment
Von  Hippel–Lindau disease is associated with pancreatic
involvement in approximately 75% of cases (more frequently true
cysts (90%), serous cystic tumours (12%), and neuroendocrine cystic
tumours (12%) or combined lesions (11%)).
The development of extra-pancreatic neoplasms is reported in
10–40% of patients with IPMNs, and they most frequently include
benign colonic polyps, and colorectal, breast and gastric cancer.
Family  history of pancreatic cancer is reported as a risk factor
for malignant degeneration in IPMNs, although this observation has
not been conﬁrmed in large cohorts of resected patients.
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Increased serum CA 19-9 levels can be associated with an
ncreased risk of malignant degeneration in IPMNs; however,
 negative result of CA 19-9 assessment does not exclude the
resence of malignancy. Onset/worsening diabetes mellitus may
e related to the presence of a ductal carcinoma in patients with
PMNs.
5) In asymptomatic patients, can morphological ﬁndings of CPNs
ndicate treatment directly?
Statement
An enhancing solid component within the cyst repre-
ents an indication for treatment. For IPMNs, the presence
f a main duct >10 mm is another indication for treatment
24,25,27,28,58,60–67].
Evidence level 2a, Recommendation grade B, Agreement 76%
Comment
Other  suspicious morphological features include: cyst diameter
3 cm;  thickened enhancing cyst wall; main duct size 5–9 mm,
 non-enhancing mural nodule, and an abrupt change in the
alibre of the pancreatic duct with distal pancreatic atrophy. These
atter suspicious features represent an indication for an additional
iagnostic work-up, including EUS with ﬁne needle aspiration
FNA) and cytology; in the case of a mucinous content of the cyst,
urgery is indicated.
6)  In asymptomatic patients, which technique/s is/are necessary
or either treating or following up patients with pancreatic cystic
esions?
Statements
In asymptomatic patients, high resolution imaging tech-
iques, including MRI  with MRCP and/or MDCT with a
ancreatic protocol, represent the ﬁrst diagnostic step [12,35,49,
1,60,62,68–77].
When “suspicious” morphological features are identiﬁed or
n patients with an uncertain radiologic diagnosis (i.e. small
ranch-duct IPMNs versus small SCNs), EUS with FNA for cytol-
gy is recommended [12,35,49,51,60,62,68–77].
Evidence  level 4, Recommendation grade C, Agreement 85%
Comment
“Suspicious” morphological features represent an indication for
n additional diagnostic work-up, including EUS with FNA; eval-
ation of the intracystic CEA level is not useful in differentiating
etween benign and malignant cysts.
Different variables should also be considered: (1) patient
ge and comorbidities (i.e. consider surgery in young patients),
2) patient willingness to undergo close follow-up evaluations
nd (3) patient family history of pancreatic cancer (i.e. consider
urgery if there are 2 family members with pancreatic cancer).
n the setting of patients with suspicious morphological features,
erum CA 19.9 level could be useful in choosing the most appro-
riate approach (i.e. surgery for those with elevated CA 19.9 levels).
7) In asymptomatic patients without morphological indications
or treatment, which medical history-laboratory-demographic data
hange the decision to treat?
Statement
A family history of pancreatic cancer (≥2 ﬁrst degree fam-
ly members) represents an indication for surgical resection of
ucinous cysts, even in patients without morphological indica-
ions for treatment [11,49,58].
Evidence level 4, Recommendation grade C, Agreement 62%
Comment
In  deciding whether to treat, type of lesion (MCN or IPMN), size,
ite, multifocality and age of the patient should be considered.r Disease 46 (2014) 479–493 481
In addition to a family history of pancreatic cancer, other
data from medical history-laboratory-demography which could
change the decision to treat the patient include: young age at
onset with long life expectancy, elevated CA 19-9 antigen, the
possibility of performing a parenchyma-sparing resection and
strong willingness of the patient to be treated.
8) Do CPNs of the pancreas exclude the patient from organ trans-
plantation?
Statement
No, CPNs of the pancreas do not exclude the patient from
organ transplantation [89].
Evidence level 4, Recommendation grade C, Agreement 91%
Comment
Careful  evaluation and characterisation of the cyst is how-
ever important, particularly if a mucinous cyst (IPMN/MCN) is
suspected. In all cases, FNA for cytology is recommended. If “sus-
picious” features are present, a more aggressive approach should
be considered before transplantation.
9)  Which diagnostic work-up is required in organ transplant
candidates with evidence of a cystic lesion of the pancreas but
without morphological characteristics of malignancy?
Statement
MRI/MRCP and EUS with FNA are recommended in organ
transplant candidates. Laboratory tests including CA 19.9 and
glucose levels and a careful clinical evaluation for cyst-related
symptoms should be carried out [82].
Evidence level 4, Recommendation grade C, Agreement 93%
Comment
Even  if the level of evidence based on the literature is low, all
available diagnostic tests can be recommended in order to improve
the possibility of identifying a malignancy and to stratify the risk
of these patients.
Regarding the follow-up of patients in which observation has
been chosen, the aims of a follow-up are: (1) to demonstrate size
variations over time (either as a cystic lesion increases or decreases
in size, or disappears); (2) to conﬁrm diagnosis (test of time), the
following questions arise.
10) What is the imaging test of choice for follow-up?
Statement
The imaging test of choice for follow-up is MRI  with MRCP.
At  any follow-up evaluation, a careful clinical examination
to identify symptoms plus laboratory tests including, CA 19.9
and glucose levels have to be carried out, especially in mucinous
lesions [13,19,49,61,62,65,76,78–87].
Evidence level 2a, Recommendation grade B, Agreement 81%
Comment
The  test of choice for follow-up evaluation depends on the ini-
tial characterisation of the cyst. Especially in SCNs, cyst size should
be evaluated over time and US could therefore be used. If there is
cyst growth and/or the presence of symptoms, then MRI  with MRCP
or CT should be performed. In branch-duct IPMNs without “suspi-
cious” features, MRI  with MRCP plus laboratory tests, including CA
19.9 and glucose levels should be carried out.
In patients with “suspicious” features or with modiﬁcations of
the cyst (i.e. an increase in size even if to less than 3 cm), EUS with
FNA should be considered.11)  What is the correct timing of a follow-up?
Statement
Follow-up should be carried out on a yearly basis and be
related to the morphological characteristics of the cystic lesion,
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 family history of pancreatic cancer, diabetes mellitus and
erum CA 19-9 levels [13,19,49,61,62,65,76,78–88].
Evidence  level 3, Recommendation grade B, Agreement 91%
Comment
A  suggested timing for follow-up according to the type of cystic
esion is reported in Table 2.
12) In the transplanted patient does the presence of an asymp-
omatic cystic lesion of the pancreas without morphological aspects
f malignancy require alternative follow-up strategies of diagnostic
ests and timing?
Statement
No,  in the transplanted patient follow-up strategies do not
iffer [89].
Evidence level 4, Recommendation grade C, Agreement 87%
Comment
Transplant recipients usually undergo immunosuppressive
reatment  to prevent rejection. It could be hypothesised that
mmunosuppressive therapy could increase the risk of tumour
egeneration of pre-neoplastic lesions, such as branch-duct IPMNs.
owever, this hypothesis is not supported by current evidence.
herefore, diagnostic tests and follow-up timing do not require
lternative strategies in this speciﬁc setting.
.2. Laboratory tests, serum markers
1) Is hyperglycaemia a marker of malignant behaviour for pan-
reatic cystic neoplasms?
Statement
Hyperglycaemia by itself is not a marker of malignant
ehaviour for pancreatic cystic neoplasms.
Evidence level 5, Recommendation grade D, Agreement 98%
Comment
A  recent diagnosis or worsening of diabetes was  found to be
ore common among malignant IPMNs [90] while no signiﬁcant
ifferences were found in the frequency of worsening of dia-
etes when comparing the subgroups with benign and malignant
umours [91].
Long-standing diabetes mellitus is considered a risk factor for
ancreatic adenocarcinoma while new-onset diabetes mellitus is
onsidered a unique form of diabetes mellitus which is caused by
he cancer [91–93].
Type  II diabetes mellitus is common in the general pop-
lation and pancreatic cancer is relatively uncommon; the
able 2
uggested follow-up timing according to the type of cystic lesion.
Type of cystic
lesion
Follow-upa
SCN Yearly imaging If no growth occurs for 3
years, consider to stop the
follow-up
MCN  and main
duct  IPMN
Resection and no speciﬁc
follow  up recommendations
Branch  duct IPMN Diameter less than 10 mm Every 12 months
Diameter  10–20 mm Every 6–12 months
Diameter  greater than 20 mm Every 3–6 months
If  after two years from initial
diagnosis  the branch duct
IPMN  is stable, follow-up
timing  can be modiﬁed as
follows:
Diameter less than 10 mm Every 24 months
Diameter  10–20 mm Every 18 months
Diameter  greater than 20 mm Every 12 months
a See statement 5, cross sectional imaging, for imaging choices.r Disease 46 (2014) 479–493
two forms of diabetes are not clinically distinguishable
[94].
2)  Is direct hyperbilirubinemia a marker of malignant behaviour
for a pancreatic cystic neoplasm located in the head of the gland?
Statement
An  isolated increase in direct bilirubinemia is not a speciﬁc
marker of malignant behaviour for a pancreatic cystic neoplasm
located in the head of the gland, although increased bilirubin
levels should prompt additional investigation.
Evidence level 5, Recommendation grade D, Agreement 85%
Comment
Jaundice  as a clinical sign has indeed been evaluated in pancre-
atic cystic neoplasms located in the head of the gland. In two  cohort
studies of patients with main/branch duct IPMNs, jaundice was sig-
niﬁcantly more frequent in the subgroups with malignant tumours
[90,91].
In a retrospective review of 166 resections of cystic tumours
≤3 cm in size, jaundice signiﬁcantly correlated with malignancy
[51]. However, in these studies, jaundice was only reported as a
sign and neither elevation of serum bilirubin nor the best cut off to
apply was  characterised.
3)  What is the post-test probability that an abnormal serum
CA19.9 level indicates malignant behaviour in a pancreatic cystic
neoplasm?
Statement
CA19.9 is not a marker of CPN malignancy. However, serum
CA19.9 determination provides additional information within
the diagnostic work-up since a positive result is associated with
the presence of an invasive carcinoma with a speciﬁcity ran-
ging from 79 to 100% and a PPV of 74%. Conversely, a negative
result does not exclude the presence of a malignancy (sensitivity
37–80%) [95–101].
Evidence level 4, Recommendation grade C, Agreement 84%
Comment
The  degree of increase in CA 19-9 levels may be useful in
differentiating pancreatic adenocarcinoma from inﬂammatory
conditions of the pancreas. On the contrary, circulating CA19.9
is not effective for distinguishing pancreatic cancer from benign
pancreatic diseases since the speciﬁcity and sensitivity of CA19.9
are not adequate for reaching an accurate diagnosis. CA19.9 is
frequently elevated in patients with jaundice, independently of the
cause of the biliary tract obstruction and it may not be elevated in
small malignant tumours of the pancreas. People lacking the Lewis
antigen (5% of the general population) are unable to synthesise
CA19.9 [102–104].
4)  Does any speciﬁc caution exist in order to obtain a repro-
ducible result of circulating biomarkers when measured in serial
determinations?
Statement
CA19.9 determination must be performed in the same labora-
tory and with the same method when evaluating serial samples
from the same patient.
Evidence  level 5, Recommendation grade D, Agreement 92%
Comment
The  inter-method variability of a CA19.9 assay is still elevated,
as shown by external quality assurance programmes. When the
method is changed, the levels of CA19.9 must be determined
by both assays on two  to four serial samples for each patient in
order to establish new reference values and an appropriate cut-off
[105,106].
5) Does any combination with other serum tests increase the
diagnostic performance of CA19.9?
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Statement
The association of other circulating markers does not provide
dditional information for differentiating benign from malig-
ant CPNs and is not recommended.
Evidence  level 4, Recommendation grade C, Agreement 100%
Comment
Available  evidence does not support the determination of CEA,
ther mucin markers or amylase in differentiating benign from
alignant CPNs.
.3.  Imaging and nuclear medicine
1) Which is the best imaging modality (US/CEUS, MDCT,
RI–MRCP, secretin MRCP or FDG-PET) in differentiating between
enign and malignant cystic pancreatic lesions?
Statements (Agreement 77%)
Conventional US of the pancreas is not able to deﬁnitively
iagnose CPNs.
Evidence  level 5, Recommendation grade C
The different dynamic imaging modalities (CEUS, MDCT, MR)
ave a similar high accuracy.
Evidence level 1b, Recommendation grade A
Available data do not support the use of S-MRCP in the dif-
erential diagnosis of benign versus malignant CPNs.
Evidence level 5, Recommendation grade D
The accuracy of FDG-PET-CT is high.
Evidence level 1b, Recommendation grade B
Comment
US of the pancreas is not able to deﬁnitively diagnose CPNs and
EUS is affected by the same technical limitations. When CPNs are
ell visible at ultrasound, in the differential diagnosis between
enign and malignant CPNs, CEUS has a sensitivity, speciﬁcity, PPV,
PV and accuracy ranging from 79% to 94%, 76% to 99%, 66% to 90%,
4% to 98% and 84% to 98%, respectively [107–110].
In the identiﬁcation of intra-cystic nodules, CEUS has a sensitiv-
ty, speciﬁcity, PPV, NPV and accuracy of 75%, 96%, 85.7%, 92.3% and
0.9%, respectively while, in the identiﬁcation of septa, CEUS has a
ensitivity, speciﬁcity, PPV, NPV and accuracy of 93%, 88%, 87%, 94%
nd 90%, respectively [110].
In cases of IPMNs, CEUS has a sensitivity of 88.2% in identifying
nhancing solid nodules [111]. MDCT is accurate in differentiat-
ng benign from malignant CPNs with an accuracy of 71–84% [112]
nd an AUROC (accuracy calculated using ROC curves) ranging from
.64 to 0.86 [113–115]. The sensitivity, speciﬁcity, PPV and NPV are
7–69%, 63–83%, 25–80% and 73–78%, respectively [112–115]. The
PVs and NPVs were higher for non-mucinous than for mucinous
PNs, and for CPNs > 3 cm [113].
In cases of mucinous cystoadenoma, CT can predict malignancy
ith a sensitivity and speciﬁcity of 81% and 83%, respectively. The
resence of septa or parietal calciﬁcations, thick walls or thick septa
s highly suggestive of malignancy: when all are present, the likeli-
ood of malignancy is 94% and when all are absent, the likelihood
f malignancy is 2% [116].
In  the differential diagnosis between benign and malignant
PNs, MR  with MRCP has a sensitivity and speciﬁcity of 94% and
5%, respectively [117], an accuracy of 73–81% [112,114] and
UROC values of 0.73–0.91 [112,114,115,117,118].  MR  is able to
xclude the malignancy of CPNs with an NPV of 74–96% [112–114].
In cases of IPMNs, in the diagnosis of benignity vs. malignancy
ccording to some “suspicious” features, MDCT has a sensitiv-
ty, speciﬁcity and accuracy of 70%, 87% and 76%, respectively
119]. With different criteria (mural nodule > 3 mm,  main pan-
reatic duct > 6 mm)  MDCT has a sensitivity, speciﬁcity, PPV, NPV
nd accuracy of 83%, 81%, 85%, 78% and 82%, respectively [120].
s regards speciﬁc “suspicious” features, for septa, MDCT has ar Disease 46 (2014) 479–493 483
sensitivity of 85% [112], and for nodules within CPNs, it has a sen-
sitivity of 0–100% [112,119].
MDCT,  also thanks to curved MPR  post-processing [121], has a
high capacity for assessing the presence of communication with the
main pancreatic duct, with a sensitivity of 83–87% [112–119] and
an AUROC of 0.774–0.790 [121].
As regards speciﬁc “suspicious” features in CPNs, for septa MR
has a sensitivity of 91–94% [110,112,118], a speciﬁcity, PPV and
NPV of 61%, 66% and 91%, respectively [110] and an accuracy of
75–95% [110,118]; for nodules, MR  has a sensitivity of 33–87%
[110,112,118], a speciﬁcity, PPV and NPV of 80%, 58% and 95%,
respectively [110], and an accuracy of 71–81% [110,118].
In  cases of IPMNs, in the diagnosis of benignity vs. malignancy
according to some “suspicious” features (nodules, main pancreatic
duct > 10 mm,  thick septa, calciﬁcations), MR  with MRCP has a sen-
sitivity, speciﬁcity and accuracy of 70%, 92% and 80%, respectively
[119].
MR with MRCP has a high capacity for assessing the pres-
ence of communication with the main pancreatic duct, with
a sensitivity and speciﬁcity of 91–100% and 89%, respectively
[112,117], an accuracy of 90% [118] and an AUROC of 0.91–0.94
[117,121].
The majority of studies published focus on IPMNs, indicating
that 18FDG-positive studies have a high speciﬁcity in detecting
malignancy [66,122–124]. In a prospective study, the sensitivity,
speciﬁcity, positive and negative predictive values, and accuracy of
18FDG-PET in detecting malignant cystic pancreatic lesions were
94%, 94%, 89%, and 97%, respectively [125].
The sensitivity (94%) and speciﬁcity (100%) of 18FDG-PET-CT
in depicting malignant cystic pancreatic lesions have been shown
to be superior to those of 18FDG-PET (sensitivity 56%, speci-
ﬁcity 83%) and CT (sensitivity 81%, speciﬁcity 100%) separately
[126].
2) Which is the best imaging modality (US/CEUS, MDCT,
MRI–MRCP, secretin MRCP or FDG-PET) for differentiating between
mucinous and non-mucinous cystic pancreatic lesions?
Statement
MDCT and MR  are the best imaging modalities for differen-
tiating mucinous and non-mucinous CPNs, both having high
accuracy.
E 1b, R A
There are no corresponding detailed data on CEUS and 18FDG-
PET. Data supporting the use of S-MRCP are not available.
E  5, R D
Agreement 78%
Comment
MDCT  has high accuracy in differentiating mucinous from non-
mucinous CPNs, ranging from 71 to 85% [112,113]. Accuracy is
higher for CPNs > 3 cm (AUROC 0.90–0.93) than for smaller ones
(AUROC 0.82) [113]. CT imaging ﬁndings suggesting a SCN are
microcystic appearance, lobulated margins and a central scar. Only
a microcystic appearance is signiﬁcantly associated with the diag-
nosis of SCN. A central scar has a sensitivity, speciﬁcity and PPV of
32%, 100% and 100%, respectively. The combination of microcys-
tic appearance and lobulated margins has a sensitivity, speciﬁcity
and PPV of 68%, 100% and 100%, respectively [127]. To differen-
tiate IPMNs from other CPNs, MDCT has a sensitivity, speciﬁcity,
PPV, NPV and an AUROC of 80%, 86%, 89%, 76% and 0.850–0.875,
respectively [121].
MR  has a sensitivity of 91% [128] and an accuracy of 78–81%
[112] in differentiating mucinous from non-mucinous CPNs. To dif-
ferentiate IPMNs from other CPNs, MR  has a sensitivity, speciﬁcity,
PPV, PNV and an AUROC of 96%, 90%, 92%, 95% and 0.932–0.995,
respectively [121].
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3) What is the role of the different imaging techniques in
atients with CPNs (diagnostic algorithm)?
Statements (Agreement 72%)
MR and MDCT are ﬁrst level techniques in differentiating
enign from malignant CPNs. The performance of CEUS is simi-
ar to that of MR  and MDCT, when CPNs are visible at US.
Evidence  level 1b, Recommendation grade A
MR with MRCP is the best imaging modality for evaluating
he communication of CPNs with the main pancreatic duct.
Evidence  level 1b, Recommendation grade A
Based on the above statements, MR  with MRCP is the imaging
ethod of choice for the study of CPNs.
Evidence level 5, Recommendation grade C
18FDG-PET must be considered as second level if clinical sus-
icion for malignancy is high and other imaging modalities are
nconclusive or if other imaging modalities are suspicious for
alignancy but have a low level of conﬁdence.
Evidence level 5, Recommendation grade D
Comment
MR with MRCP is highly reliable in assessing the presence of
ommunication with the main pancreatic duct, having a sensitiv-
ty and speciﬁcity of 91–100% and 89%, respectively [112,117], an
ccuracy of 90% [118] and an AUROC of 0.91–0.94 [117,121].
MR  is the standard of reference in the diagnostic management
f CPNs; it is mandatory in young patients and women of fertile
ge.
MDCT has slightly lower capacity of assessing the presence of
ommunication with main pancreatic duct, having a sensitivity of
3–87% [112,119] and an AUROC of 0.774–0.790 [121], but it is
ore invasive.
S-MRCP has a limited value in the management of CPNs; it can
e useful in clarifying the presence of communication between the
PNs and the main pancreatic duct which is not clear in standard
RCP.
Proposed diagnostic algorithm:
.  US diagnosis of CPNs.
. MRI  or MDCT for characterising and differentiating benign from
malignant  CPNs.
. In cases of unclear communication between the CPN and main
pancreatic  duct: S-MRCP.
. In cases of unclear imaging ﬁndings for malignancy with high
clinical  suspicion: 18FDG-PET.
4)  What is the role of percutaneous guided sampling?
Statement
There are no data supporting the role of percutaneous guided
ampling of CPNs. The FNA of CPNs has to be performed using
he EUS approach.
Evidence level 5, Recommendation grade D, Agreement 89%
Comment
The  EUS approach for FNA of CPNs is preferable and supported
y data in the literature.
5)  What is the role of the different imaging techniques (US/CEUS,
DCT, MRI–MRCP, secretin MRCP and18FDG-PET-CT) in the follow-
p of patients with asymptomatic CPNs?
Statements (Agreement 78%)
The role of any individual method depends on both the size
nd the number of CPNs.. Small single cyst (<1 cm)  visible at US: US is preferred until
size  change occurs. If size change occurs, CEUS or MR  imaging
should  be performed to evaluate the presence of “suspicious”r Disease 46 (2014) 479–493
features. MR  with MRCP, alternated with US,  should be used to
evaluate the development of new CPNs. If MR identiﬁes new
CPNs,  a follow-up must be carried out with MR.
. Small single cyst (<1 cm)  not visible at US: MR/MRCP.
Evidence  level 5, Recommendation grade D
c.  Large single cyst (≥1 cm)  visible at US: US is preferred until
size  change occurs. If size change occurs, CEUS or MR  imaging
should  be performed to evaluate the presence of “suspicious”
features  (size, nodules, septa, content, morphology). MR with
MRCP, alternated with US, is used to evaluate the develop-
ment  of new CPNs. See above Comment for small lesions.
. Large single cyst (≥1 cm)  not visible at US: MR  with MRCP or
MDCT.  In cases with strict follow-up (e.g. 3 months), MDCT
should  be used only in older patients without renal insufﬁ-
ciency  or in patients with absolute contraindications to MR.
Evidence level 5, Recommendation grade D
e. Multiple cysts: MR  with MRCP
Evidence level 5, Recommendation grade D
S-MRCP is not indicated in the follow-up due to the limited
information provided.
Evidence  level 1b; Recommendation grade A
18FDG-PET is not indicated in the follow-up due to high
costs  and radiation exposure issues.
Evidence level 5, Recommendation grade D
2.4.  EUS/endoscopy
1)  What is the role of EUS in differentiating between benign and
malignant CPNs?
Statement
EUS  can identify morphological features which increase the
suspicion of malignancy in CPNs. However, morphologic fea-
tures identiﬁed at EUS alone cannot exclude the presence of
malignancy in CPNs.
Evidence  level 2b, Recommendation grade B, Agreement 91%
Comment
Two  studies regarding the EUS features [129,130] of resected
IPMNs showed that “suspicious” features were signiﬁcantly
(P < 0.05) associated with malignant lesions. On the basis of
these morphological features, the accuracy of EUS for malignancy
was 86%. EUS is more sensitive than MDCT in detecting solid
components in IPMNs (84% EUS vs. 68% MDCT), less speciﬁc (33%
EUS vs. 100% MDCT) but with similar accuracy (76.5% EUS vs. 70.6%
MDCT) [131]. However, the usefulness of EUS  in distinguishing
mucus from mural nodules has been recently assessed [82,132],
with a 75% sensitivity and 83% speciﬁcity versus a 24% sensitivity
and 100% speciﬁcity of CT.
2) What is the role of EUS in differentiating between mucinous
and non-mucinous pancreatic CPNs?
Statement
Although EUS morphology alone cannot provide a deﬁnite
differential diagnosis between mucinous and non-mucinous
CPNs, some EUS features offer useful information on the type
of lesion.
Evidence level 4, Recommendation grade C, Agreement 96%
Comment
A  review [133] of seven studies [78,134–139] regarding the
diagnostic accuracy of EUS morphology in differentiating muci-
nous and non-mucinous CPNs, reported accuracies ranging from
51 to 90%. Interobserver agreement between endosonographers
in the diagnosis of CPNs appears low [138,140,141]. Conversely,
EUS shows some cystic features which are speciﬁc for different
types of CPNs [40,134–138,142,143].  EUS and MRI  have similar
sensitivities in identifying communication with the main pancre-
atic duct (100% for MRI  vs. 88.9% for EUS, P = >0.8), particularly in
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he diagnosis of branch-duct IPMNs [118]. EUS allows the visual-
sation of multifocal CPNs, which are usually suggestive of IPMNs
61,144] better than cross-sectional imaging (13% for CT vs. 47% for
US, P = <0.0001 and 34% for MRI  vs. 58% for EUS, P = <0.0002) [144].
3) Does the use of contrast during EUS increase the diagnostic
ccuracy of EUS for CPNs?
Statement
Contrast-enhanced EUS may  be helpful in the differential
iagnosis of CPNs and in ruling out neoplastic degeneration. The
nalysis of intracystic nodules at contrast-enhanced EUS may
elp in differentiating neoplastic vegetations from mucus and
ebris.
Evidence level 4, Recommendation grade C, Agreement 96%
Comment
The  literature on the use of contrast in the differential diagnosis
f CPNs is very limited. SCNs typically appear hyperenhanced at
ontrast-enhanced EUS; the signal is detected inside the septa
nd cyst wall [145]. In the context of IPMNs, intracystic nodules
hat are tumoural may  show some degree of enhancement, unlike
ucus plugs and debris which are non enhanced [132].
4)  What is the expected complication rate of diagnostic EUS?
Statement
The  expected complication rate of diagnostic EUS is very low
nd is estimated to be approximately 0.03% [146–149].
Evidence level 2a, Recommendation grade B, Agreement 98%
Comment
Echoendoscopes are the most difﬁcult instruments to use in
igestive endoscopy. Oesophageal and duodenal perforations are
he most common complications [150–156].
5) When is EUS-FNA recommended for differentiating between
enign and malignant CPNs?
Statement
EUS-FNA is indicated when a previous diagnostic modal-
ty has shown CPNs with “suspicious” features other than an
nhancing solid component, when the other diagnostic modal-
ties fail to obtain a deﬁnite diagnosis, or in cases of advanced
alignant CPNs when chemotherapy is considered.
Evidence level 2a, Recommendation grade B, Agreement 91%
Comment
EUS-FNA  can target areas inside the lesion which are not obtain-
ble by other bioptic modalities. In the differential diagnosis of
enign and malignant CPNs, prospective and retrospective studies
ave shown that cytology seems to be more accurate than ﬂuid
nalysis, with accuracy rates ranging from 75 to 88% [137,157,158];
he adequacy of cytological sampling in CPNs ranges from 30 to
0%; the combination of cytology and ﬂuid analysis is the best
odality for diagnosing malignant lesions [118,159–164].
6) When is EUS-FNA recommended in the differential diagnosis
etween mucinous and non–mucinous CPNs?
Statement
EUS-FNA is indicated when the other diagnostic modalities
ail to obtain a deﬁnite differential diagnosis.
Evidence level 2a, Recommendation grade B, Agreement 96%
Comment
In  the differentiation between SCNs vs. branch-duct IPMNs and
CNs, EUS-FNA is the only method which can obtain a diagnosis
ith accuracy rates near 80%. In this setting, CEA levels in the cyst
uid provide the best predictor; the most valuable cut-off for SCN
iagnosis is CEA < 5 ng/ml while the best cut-off to differentiate a
ucinous lesion is CEA > 192 [33,78,159,165–167].r Disease 46 (2014) 479–493 485
A size of 1.5 cm is the minimum required to obtain ﬂuid for at
least one analysis which should be CEA [55].
EUS-FNA is not necessary if surgery is planned irrespectively of
the differentiation between serous and mucinous CPNs.
7)  Are there any data available regarding particular needles,
devices, sampling techniques or ROSE (rapid on-site evaluation) of
the sampled material which increase the performance of EUS-FNA
of CPNs?
Statement
Both cytology brush, which allows brushing of the walls in
CPNs, and targeted cyst wall biopsy, using either the trucut
biopsy needle or a standard EUS-FNA needle, showed better
results than only cytological samples from FNA of cystic ﬂuid.
No data are available regarding ROSE in CPNs.
Evidence level 2b, Recommendation grade B, Agreement 91%
Comment
Although  better results for both the cytobrush-needle and the
trucut needle than with standard needles were reported [168–172],
one study showed poorer results [169] and two studies [168,171]
observed an elevated rate of complications (8–10%), including one
fatality. Both the trucut and the cytobrush needles (requiring a 19-
gauge needle) had technical limitations in lesions of the pancreatic
head and uncinate process [168–170,173].
Confocal microscopy probes [174] and optical catheters [175]
have been used in small case series to directly visualise the cyst
lining and are still considered experimental.
8) What is the expected complication rate from EUS-FNA?
Statement
EUS-FNA of CPNs has a rate of intra-cyst haemorrhage of
approximately 4%. Bleeding is usually self-limiting. No death
has been reported after EUS-FNA performed in the standard
modality with standard needles. Different risks of complica-
tions have been reported with different technical modalities of
FNA or using different devices.
Evidence level 4, Recommendation grade C, Agreement 94%
Comment
A  signiﬁcantly higher incidence of complications for EUS-FNA of
CPNs than for pancreatic solid lesions (14% vs. 0.5%); P < 0.001) has
been reported [176–179].
Haemorrhage is usually caused by needle passage through the
cyst wall, or by scratching the distal wall or septa with the needle
tip (to increase the yield of cytology).
Other reported complications are anecdotal and include pan-
creatic ﬁstula, acute pancreatitis, pancreatic abscess and infection.
9a) Does antibiotic prophylaxis reduce the infectious complica-
tion rate of EUS-FNA of CPNs?
Statement
There is insufﬁcient data to demonstrate that antibiotic pro-
phylaxis reduces the rate of infectious complications.
Evidence level 5, Recommendation grade D, Agreement 87%
Comment
Even  if no increase in the rate of bacteraemia has been demon-
strated after EUS-FNA in comparison to upper GI endoscopy,
the incidence of infectious complications using antibiotic pro-
phylaxis was low (0–1.4%); on the basis of these data, antibiotic
prophylaxis is commonly applied in everyday clinical practice;
ﬂuoroquinolones or betalactam antibiotics administered intra-
venously before the procedure and orally for 3–5 days thereafter
are the most commonly used regimens [155,180–182].
9b) Are there safety differences regarding needles or devices for
EUS-FNA of CPNs?
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Statements (Agreement 98%)
For FNA of pancreatic lesions, 19G, 22G, 25G standard needles
ave similar safety proﬁles [172,183,184].
Evidence level 1c, Recommendation grade A
Standard FNA needles are safer than cytology brush and tru-
ut biopsy needle [168,173].
Evidence  level 2c, Recommendation grade B
Comment
The use of brushing devices is associated with an increase in
omplication rates [168,171], and should be limited to selected
ases.
Trucut biopsy needles targeted on the cystic wall may  provide
istological material, thus guiding management decisions but, due
o their increased risk of complications, they are not currently
ndicated.
9c) Does the sampling technique reduce the complication rate
f EUS-FNA for CPNs?
Statement
There  is in sufﬁcient data to demonstrate that the sampling
echnique reduces the complication rate of EUS-FNA for CPNs.
Evidence  level 5, Recommendation grade D, Agreement 95%
Comment
Based  on expert opinion, the following recommendations can,
owever, be made:
 to minimise the risk of pancreatitis, the site of the puncture must
be  as close as possible to the cyst to reduce puncturing normal
pancreas.
 to minimise the risk of bleeding, the presence of blood vessels on
the needle track must be excluded by Doppler imaging.
 no more than one needle pass is recommended to decrease the
risk  of bleeding and infections.
 suction must be applied to the needle in order to empty the cyst
as  much as possible to prevent infection [185–189].
9d)  Does ROSE (rapid on-site evaluation) of the material sam-
led increase safety of EUS-FNA of CPNs?
Statement
There are no data as to ROSE increasing the safety of EUS-FNA
f CPNs.
Evidence level 5, Recommendation grade D, Agreement 92%
Comment
In  the case of solid mural nodules of the cystic lesion, more than
ne passage can be necessary and, in this case, we  can assume the
ame role for ROSE as for solid lesions.
10) What is the diagnostic role of ERCP in patients with CPNs?
Statement
Diagnostic  ERCP for the evaluation of CPNs is indicated only
f endoscopic views of the papillary area, pancreatoscopy, or
ntraductal ultrasound (IDUS) are still required at the end of
he diagnostic work-up for a deﬁnite diagnosis in patients with
uspected IPMNs.
Evidence  level 4, Recommendation grade C, Agreement 93%
Comment
Duodenoscopy can display the highly speciﬁc ﬁnding of mucus
xtruding from a patulous papilla of Vater in 20–55% of IPMNs. It
an also display duodenal invasion/stenosis and a pancreatic duo-
enal ﬁstula extruding mucus (suggesting malignant evolution) in
% of IPMNs [189–192].Pancreatic  juice and tissue sampling can also be obtained during
RCP, however, with conﬂicting results. The routine use of ERCP
or analysing pancreatic juice, CEA or tissue sampling is no longer
ecommended in branch duct type IPMNs [193].r Disease 46 (2014) 479–493
Pancreatoscopy permits precise sampling under the direct view
of ductal ﬁlling defects or strictures, allowing a differential diagno-
sis among vegetations, mucus and stones [194–200].
Retrograde cholangiography can detect biliary obstructions
which can develop during the course of IPMNs due to malignant
inﬁltration or external compression [200,201].
IDUS can detect communication between CPN and the pancre-
atic duct, minute mural nodules in IPMNs or the precise extension
of ductal vegetations which may  have been missed by other imag-
ing techniques [76,202]. Combining pancreatoscopy and IDUS in
IPMNs increases the ability of differentiating benign from malig-
nant disease with an accuracy of 88% [189,191].
2.5. Laboratory markers in cystic ﬂuid
1) Is the determination of intracystic CEA useful in the differen-
tial diagnosis between benign and malignant CPNs?
Statement
Intracystic CEA is not accurate in differentiating malignant
from non-malignant CPNs.
Evidence level 2a, Recommendation grade B, Agreement 95%
Comment
Individual  CEA values overlap between benign and malignant
mucinous CPNs [98,118,55,203].
2)  Is determination of intracystic CEA useful in the differential
diagnosis between mucinous and non-mucinous CPNs?
Statement
Increased CEA levels in the cystic ﬂuid are helpful in distin-
guishing mucinous from non-mucinous CPNs.
Evidence level 2a, Recommendation grade B, Agreement 96%
Comment
Although  a positive/negative threshold level of 192 ng/ml is fre-
quently reported for the cystic ﬂuid CEA level, the cut-off level
required to best differentiate mucinous from serous lesions has not
yet been established.
Fluid  analysis with a CEA > 800 ng/ml is speciﬁc (98–100%)
for mucinous cystic adenoma or carcinoma, with a PPV of 94%.
Six percent of the CPNs having CEA level of <5 ng/ml may  be a
mucinous cystic adenoma or a carcinoma [55,203,204,79,205].
3) Is determination of intracystic CA19.9 useful in the differen-
tial diagnosis between benign and malignant CPNs?
Statement
Intracystic CA19.9 is not accurate in differentiating malig-
nant from non-malignant CPNs.
Evidence level 3c, Recommendation grade B, Agreement 96%
Comment
Individual  CA19.9 values overlap between benign and malig-
nant CPNs [42,55].
4)  Is determination of intracystic CA19.9 useful in the differen-
tial diagnosis between mucinous and non-mucinous CPNs?
Statement
CA19.9  measured in the cystic ﬂuid has been reported to
provide additional information within the diagnostic work-up
in CPNs in which the CEA level is indeterminate.
Evidence level 3c-2a, Recommendation grade C, Agreement 86%
Commentnot been determined, a CA 19-9 level lower than the cut-off level
used in serum is associated with a serous type having a sensitivity,
speciﬁcity, PPV, NPV and accuracy of 19%, 98%, 94%, 38% and 46%,
respectively [55].
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5) Is determination of intracystic pancreatic enzymes use-
ul in the differential diagnosis between benign and malignant
PNs?
Statement
The determination of pancreatic enzymes in the cystic ﬂuid
s not useful in the differential diagnosis between benign and
alignant CPNs [57,95,98,55,206].
Evidence level 3c, Recommendation grade B, Agreement 100%
Comment
Assaying  the level of lipase in the cystic ﬂuid is discouraged due
o the unsatisfactory nature of lipase methods; an amylase assay is
referred [207].
6)  Is determination of intracystic amylase useful in the differen-
ial diagnosis of CPNs?
Statement
The  determination of amylase in the cystic ﬂuid is helpful in
etermining the differential diagnosis among CPNs. High amy-
ase levels are usually associated with communication between
he pancreatic duct and the CPNs, as in the majority of IPMNs.
Evidence  level 2c, Recommendation grade B, Agreement 96%
Comment
Increased  amylase in the cystic ﬂuid from MCN  has been
eported in two studies; thus, these ﬁndings suggest caution in
nterpreting the results of amylase determination in the cystic
uid [44,205].
7)  Are any other intracystic tests recommended?
Statement
On the basis of the available evidence, no tests other than
EA, CA19.9 and amylase can be recommended.
Evidence level 2c-3, Recommendation grade C, Agreement 95%
Comment
Several  molecular markers, such as mucins, DNA quantity, K-ras
utation and allelic imbalance mutations, have been investigated.
t is currently unknown whether the results obtained can be
eliably reproduced in other laboratories [208,209,38].
8) Can a combination of intracystic tests increase the quality of
he results?
Statement
The determination of both CEA and amylase is recommended
o help in differentiating mucinous from non-mucinous CPNs.
Evidence  level 2c, Recommendation grade B, Agreement 98%
Comment
The  association of CEA and amylase is to be recommended on an
mpirical basis since the two tests provide different information.
levated CEA levels may  indicate the presence of a mucinous
esion while increased cystic ﬂuid amylase is usually associated
ith communication with the pancreatic ducts.
9) Are there speciﬁc recommendations for collecting and pre-
erving cystic ﬂuid for laboratory test analysis?
Statement
Samples must be collected according to the Good Clinical
ractice guidelines and managed according to Good Laboratory
ractice.
Evidence level 5, Recommendation grade D, Agreement 93%
Comment
Studies  on the impact of the pre-analytical phase (specimen
andling, sample preparation and storage) on laboratory test
esults are not available [210].10) Are there speciﬁc recommendations for the standardisation
f the assay method to be used in the “ﬂuid cyst matrix”?
Statementr Disease 46 (2014) 479–493 487
The analytical performance of the assay methods for mea-
suring CEA and CA19.9 (including at least intra-assay precision,
the dilution test and the recovery test) should be validated in a
matrix comparable to cystic ﬂuid.
Evidence level 5, Recommendation grade D, Agreement 100%
Comment
Assays  of markers in the cystic ﬂuid should be carried out in
experienced reference laboratories with a workload sufﬁcient for
guaranteeing method validation and ad interim evaluation of the
reliability of the methods [211].
11) Are there speciﬁc recommendations for the assessment of
positive/negative cut-off points for CEA, amylase and CA19.9 in the
cystic ﬂuid?
Statement
No  evidence exists regarding the cut-off values to be used in
clinical practice. In addition, cut-off values are partially related
to the assay method used.
Evidence level 5, Recommendation grade D, Agreement 96%
Comment
For  the assessment of cut-off values, it is mandatory to establish
a reference standard in order to properly classify true positive and
true negative cases. Most of the data available regarding the accu-
racy of markers derive from retrospective studies which employed
the histology obtained after surgery as the gold standard. Thus, the
interpretation should be cautious when the data come from retro-
spective series and refer to patients without clear morphological
indications for surgery.
Laboratories  which intend to carry out marker assays on the
cystic ﬂuid should collaborate with clinicians in order to establish
their own cut-off value on the basis of patient outcome.
2.6. Pathology
1)  What are the best methods for obtaining material from CPNs
for pathological examination?
Statement
With  FNA for pancreatic CPNs, a single pass is recommended
with aspiration of a minimum of 1 ml  of liquid. For pathologists,
the use of the 19G, 22G and 25G needles have similar diagnostic
yields [162,212].
Evidence level 2a, Recommendation grade C, Agreement 91%
Comment
The  cytopathology specimens can be procured either by EUS-
guided FNA (EUS-FNA) or by US or CT-guided, percutaneous
aspirates. However, ROSE can be used to limit the number of FNA
passes needed for solid pancreatic lesions [213–215,55,216–218],
a  single pass is recommended for CPNs.
The protocols for optimising multimodal analysis (cytology,
biochemistry, and molecular analysis) are volume dependent
whereas the technical procedures for cytological analysis should
be chosen by the individual laboratories, depending on their con-
ﬁdence with the methods available (smears, liquid based cytology,
cell-blocks).
2) Can cytological examination differentiate between benign
and malignant CPNs?
Statement
A  cytological examination is useful in the differential diag-
nosis between benign and malignant CPNs.
Evidence level 2a, Recommendation grade B, Agreement 100%
Comment
A  diagnosis of malignancy has a reported sensitivity ranging
from 22 to 95%, a speciﬁcity of almost 100%, PPV of 100%, NPV of
47–95%, and a diagnostic accuracy of 85–90%. The adequacy and
accuracy strongly depend on the overall institutional experience,
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ncluding pathologist experience, procedure-related factors, such
s instrumentation, and endoscopist skill [208,219,220].
3) How can an MCN  be differentiated from a non-MCN using
ytological examination?
Statement
The  presence of extracellular thick mucus and the recogni-
ion of an atypical epithelial cell component with intracytoplas-
ic mucin represent the diagnostic hallmark of MCNs [78,221].
Evidence level 2c, Recommendation grade B, Agreement 100%
Comment
The  pooled sensitivity and speciﬁcity in diagnosing mucinous
ystic neoplasms are 63% and 88%, respectively, and the positive
nd negative likelihood ratios are 4.46 and 0.46, respectively [222].
 diagnostic epithelial component is identiﬁable in a minority of
ases and differentiating gastric contamination from low-grade
astric-type branch duct IPMNs can be impossible.
4) What is the diagnostic value of high-grade cellular atypia?
Statement
The  presence of cells with high grade atypia is the best cyto-
ogical marker of malignant CPNs.
Evidence level 2b, Recommendation grade B, Agreement 96%
Comment
Lowering  the threshold of cytological atypia, from “positive”
or malignancy to high-grade atypia increases the prediction of
alignancy from 29 to 80%, although the speciﬁcity decreases
rom 100 to 85% [19,219].
5)  Are there any molecular analyses (i.e. DNA, mucin, K-ras and
ther substances) which can be used in clinical practice for a dif-
erential diagnosis between benign and malignant CPNs?
Statement
At  present, no molecular marker is available in clinical
ractice to differentiate benign from malignant CPNs.
Evidence  level 5, Recommendation grade D, Agreement 98%
Comment
Molecular  analyses on the cystic ﬂuid may  be helpful in dif-
erentiating benign from malignant CPNs. Cystic ﬂuid levels of
nterleukin1 [223], glycosylation variants of mucins [37], pro-
eomic analysis [224] and microRNA expression proﬁles [87,225]
re among the emerging tests under investigation which could
otentially become biomarkers in cystic ﬂuid samples.
6)  Are there any molecular analyses (i.e. DNA, mucin, K-ras and
ther substances) which can be used in clinical practice for a dif-
erential diagnosis between mucinous and non-mucinous CPNs?
Statement
At present, no molecular markers are available in clinical
ractice to differentiate mucinous from non-mucinous CPNs.
Evidence  level 5, Recommendation grade D, Agreement 96%
Comment
Although  mutations in a set of genes have recently been discov-
red in the majority of frequent CPNs, there are no molecular-based
ests which can be used in a clinical setting. The GNAS gene was
nly found in patients with IPMNs and may  be a useful marker in
he future for differentiating IPMNs from MCNs [226].
.  Future perspectivesSeveral  areas require further investigation through speciﬁc
tudies. In particular, the natural history of CPNs should be elu-
idated as the available data are still limited; studies comparing
he yield and impact of both EUS and transcutaneous imaging inr Disease 46 (2014) 479–493
similar CPNs are still lacking; laboratory examination of CPN ﬂuid
still requires standardisation.
The  scientiﬁc societies AIGO and AISP have made a com-
mitment to validate the present guidelines with a prospective
data collection; the aim will be to evaluate the improvement
of both patient management and efﬁciency in the utilisation of
resources.
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